See original here:
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh